Oppenheimer downgraded Terns Pharmaceuticals (TERN) to Perform from Outperform after the company agreed to be acquired by Merck (MRK) for $53 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Merck announces expiration of HSR waiting period to acquire Terns Pharmaceuticals
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at William Blair
- Unusually active option classes on open April 7th
- Merck begins tender offer to acquire Terns Pharmaceuticals